Charissa Chou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Charissa Chou has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Ece Dilber Gamsiz Uzun
Brown University Alpert Medical School
3 shared publications - Alper Uzun
Alpert Medical School, Brown University
2 shared publications - Yigit Baykara
Department of Pathology University of Arizona College of Medicine Tucson Arizona USA
2 shared publications Albert DeLuca
1 shared publicationAli Amin
1 shared publication- Ali Amin
Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA
1 shared publication
Latest Publications
- Open Access
- 27 November 2025
- Published by JMIR Publications Inc. in JMIR Bioinformatics and Biotechnology
- Vol. 6, e76736
Protein-Protein Interactions in Papillary and Nonpapillary Urothelial Carcinoma Architectures: Comparative Study
Background: Bladder cancer is a disease characterized by complex perturbations in gene networks and is heterogeneous in terms of histology, mutations, and prognosis. Advances in high-throughput sequencing technologies, genome-wide association studies, and bioinformatics methods have revealed greater insights into the pathogenesis of complex diseases. Network biology–based approaches have been used to identify complex protein-protein interactions (PPIs) that can lead to potential drug targets. There is a need to better understand PPIs specific to urothelial carcinoma. Objective: This study aimed to elucidate PPIs specific to papillary and nonpapillary urothelial carcinoma and identify the most connected or “hub” proteins, as these are potential drug targets. Methods: A novel PPI analysis tool, Proteinarium, was used to analyze RNA sequencing data from 132 patients with papillary and 270 patients with nonpapillary urothelial carcinoma from the TCGA Cell 2017 dataset and 39 patients with papillary and 88 patients with nonpapillary urothelial carcinoma from the TCGA Nature 2014 dataset. Hub proteins were identified in distinct PPI networks specific to papillary and nonpapillary urothelial carcinoma. Statistical significance of clusters was assessed using the Fisher exact test ( P <.001), and network separation was quantified using the interactome-based separation score. Results: RPS27A, UBA52, and VAMP8 were the most connected or “hub” proteins identified in the network specific to the papillary urothelial carcinoma. In the network specific to the nonpapillary carcinoma, GNB1, RHOA, UBC, and FPR2 were found to be the hub proteins. Notably, GNB1 and FPR2 were among the proteins that have existing drugs targeting them. Conclusions: We identified distinct PPI networks and the hub proteins specific to papillary and nonpapillary urothelial carcinomas. However, these findings are limited by the use of transcriptomic data and require experimental validation to confirm the functional relevance of the identified targets.
- 27 November 2025
- Published by JMIR Publications Inc. in JMIR Bioinformatics and Biotechnology
- Vol. 6, e76736
Open AccessProtein-Protein Interactions in Papillary and Nonpapillary Urothelial Carcinoma Architectures: Comparative Study
Background: Bladder cancer is a disease characterized by complex perturbations in gene networks and is heterogeneous in terms of histology, mutations, and prognosis. Advances in high-throughput sequencing technologies, genome-wide association studies, and bioinformatics methods have revealed greater insights into the pathogenesis of complex diseases. Network biology–based approaches have been used to identify complex protein-protein interactions (PPIs) that can lead to potential drug targets. There is a need to better understand PPIs specific to urothelial carcinoma. Objective: This study aimed to elucidate PPIs specific to papillary and nonpapillary urothelial carcinoma and identify the most connected or “hub” proteins, as these are potential drug targets. Methods: A novel PPI analysis tool, Proteinarium, was used to analyze RNA sequencing data from 132 patients with papillary and 270 patients with nonpapillary urothelial carcinoma from the TCGA Cell 2017 dataset and 39 patients with papillary and 88 patients with nonpapillary urothelial carcinoma from the TCGA Nature 2014 dataset. Hub proteins were identified in distinct PPI networks specific to papillary and nonpapillary urothelial carcinoma. Statistical significance of clusters was assessed using the Fisher exact test ( P <.001), and network separation was quantified using the interactome-based separation score. Results: RPS27A, UBA52, and VAMP8 were the most connected or “hub” proteins identified in the network specific to the papillary urothelial carcinoma. In the network specific to the nonpapillary carcinoma, GNB1, RHOA, UBC, and FPR2 were found to be the hub proteins. Notably, GNB1 and FPR2 were among the proteins that have existing drugs targeting them. Conclusions: We identified distinct PPI networks and the hub proteins specific to papillary and nonpapillary urothelial carcinomas. However, these findings are limited by the use of transcriptomic data and require experimental validation to confirm the functional relevance of the identified targets.
- Open Access
- 29 April 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Distinct protein-protein interactions define papillary and non-papillary urothelial carcinoma architectures (Preprint)
BACKGROUND Bladder cancer is a disease with complex perturbations in gene networks and heterogeneous in terms of histology, mutations, and prognosis. Advances in high-throughput sequencing technologies, genome-wide association studies, and bioinformatics methods have revealed greater insights into the pathogenesis of complex diseases. Network biology-based approaches have been used to demonstrate the complex physical or functional interactions between molecules which can lead to potential drug targets. OBJECTIVE There is a need to better understand gene networks and protein-protein interactions (PPI) specific to urothelial carcinoma. METHODS We performed a multi-sample PPI study comparing two urothelial carcinoma architectures: papillary and non-papillary. We used a novel PPI analysis tool, Proteinarium to identify clusters of patients with shared PPI networks in each architecture. The feature of this tool is to analyze the PPI networks of patients and visualize them in clusters based on their network similarities from any genomic data including Next Generation Sequencing (NGS). RESULTS We observed distinct networks for the papillary and non-papillary groups. Proteins unique to the papillary urothelial carcinoma detected in two separate datasets included UBA52, RPS27A, UBR4, CUL1, UBE2K, and CDC5L. Proteins found in the non-papillary urothelial carcinoma specific PPI network were GNB1, UBC, RHOA, FPR2, GNGT1, PIK3CA, PIK3CG, HSP90AA1, SLC11A1, CCT7, ARHGEF1, PAK1, PAK2, PSMA7, and TRIO. CONCLUSIONS We identified distinct PPI networks specific to papillary and non-papillary urothelial carcinomas presenting unique molecular entities. CLINICALTRIAL N/A
- 29 April 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDistinct protein-protein interactions define papillary and non-papillary urothelial carcinoma architectures (Preprint)
BACKGROUND Bladder cancer is a disease with complex perturbations in gene networks and heterogeneous in terms of histology, mutations, and prognosis. Advances in high-throughput sequencing technologies, genome-wide association studies, and bioinformatics methods have revealed greater insights into the pathogenesis of complex diseases. Network biology-based approaches have been used to demonstrate the complex physical or functional interactions between molecules which can lead to potential drug targets. OBJECTIVE There is a need to better understand gene networks and protein-protein interactions (PPI) specific to urothelial carcinoma. METHODS We performed a multi-sample PPI study comparing two urothelial carcinoma architectures: papillary and non-papillary. We used a novel PPI analysis tool, Proteinarium to identify clusters of patients with shared PPI networks in each architecture. The feature of this tool is to analyze the PPI networks of patients and visualize them in clusters based on their network similarities from any genomic data including Next Generation Sequencing (NGS). RESULTS We observed distinct networks for the papillary and non-papillary groups. Proteins unique to the papillary urothelial carcinoma detected in two separate datasets included UBA52, RPS27A, UBR4, CUL1, UBE2K, and CDC5L. Proteins found in the non-papillary urothelial carcinoma specific PPI network were GNB1, UBC, RHOA, FPR2, GNGT1, PIK3CA, PIK3CG, HSP90AA1, SLC11A1, CCT7, ARHGEF1, PAK1, PAK2, PSMA7, and TRIO. CONCLUSIONS We identified distinct PPI networks specific to papillary and non-papillary urothelial carcinomas presenting unique molecular entities. CLINICALTRIAL N/A
- Open Access
- 10 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (6) , 5327
MMR Deficiency Defines Distinct Molecular Subtype of Breast Cancer with Histone Proteomic Networks
Mismatch repair (MMR) alterations are important prognostic and predictive biomarkers in a variety of cancer subtypes, including colorectal and endometrial. However, in breast cancer (BC), the distinction and clinical significance of MMR are largely unknown. This may be due in part to the fact that genetic alterations in MMR genes are rare and only seen to occur in around 3% of BCs. In the present study, we analyzed TCGA data using a multi-sample protein–protein interaction (PPI) analysis tool, Proteinarium, and showed a distinct separation between specific MMR-deficient and -intact networks in a cohort of 994 BC patients. In the PPI networks specific to MMR deficiency, highly connected clusters of histone genes were identified. We also found the distribution of MMR-deficient BC to be more prevalent in HER2-enriched and triple-negative (TN) BC subtypes compared to luminal BCs. We recommend defining MMR-deficient BC by next-generation sequencing (NGS) when any somatic mutation is detected in one of the seven MMR genes.
- 10 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (6) , 5327
Open AccessMMR Deficiency Defines Distinct Molecular Subtype of Breast Cancer with Histone Proteomic Networks
Mismatch repair (MMR) alterations are important prognostic and predictive biomarkers in a variety of cancer subtypes, including colorectal and endometrial. However, in breast cancer (BC), the distinction and clinical significance of MMR are largely unknown. This may be due in part to the fact that genetic alterations in MMR genes are rare and only seen to occur in around 3% of BCs. In the present study, we analyzed TCGA data using a multi-sample protein–protein interaction (PPI) analysis tool, Proteinarium, and showed a distinct separation between specific MMR-deficient and -intact networks in a cohort of 994 BC patients. In the PPI networks specific to MMR deficiency, highly connected clusters of histone genes were identified. We also found the distribution of MMR-deficient BC to be more prevalent in HER2-enriched and triple-negative (TN) BC subtypes compared to luminal BCs. We recommend defining MMR-deficient BC by next-generation sequencing (NGS) when any somatic mutation is detected in one of the seven MMR genes.